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Abstract
Hybrid trials that include both clinical and implementation science outcomes are increasingly
relevant for public health researchers that aim to rapidly translate study findings into evi-
dence-based practice. The DeWorm3 Project is a series of hybrid trials testing the feasibility
of interrupting the transmission of soil transmitted helminths (STH), while conducting imple-
mentation science research that contextualizes clinical research findings and provides guid-
ance on opportunities to optimize delivery of STH interventions. The purpose of DeWorm3
implementation science studies is to ensure rapid and efficient translation of evidence into
practice. DeWorm3 will use stakeholder mapping to identify individuals who influence or are
influenced by school-based or community-wide mass drug administration (MDA) for STH
and to evaluate network dynamics that may affect study outcomes and future policy devel-
opment. Individual interviews and focus groups will generate the qualitative data needed to
identify factors that shape, contextualize, and explain DeWorm3 trial outputs and outcomes.
Structural readiness surveys will be used to evaluate the factors that drive health system
readiness to implement novel interventions, such as community-wide MDA for STH, in order
to target change management activities and identify opportunities for sustaining or scaling
the intervention. Process mapping will be used to understand what aspects of the interven-
tion are adaptable across heterogeneous implementation settings and to identify contextu-
ally-relevant modifiable bottlenecks that may be addressed to improve the intervention
delivery process and to achieve intervention outputs. Lastly, intervention costs and incre-
mental cost-effectiveness will be evaluated to compare the efficiency of community-wide
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MDA to standard-of-care targeted MDA both over the duration of the trial and over a longer
elimination time horizon.
Author summary
The DeWorm3 Project is a series of randomized clinical trials testing the feasibility of
interrupting the transmission of soil-transmitted helminths. We have integrated imple-
mentation science research questions into the trials in order to optimize delivery of trial
interventions as well as to speed the translation of study evidence into relevant policy and
practice. DeWorm3 implementation science research will take place at baseline (formative
research), midline (process research), and endline (summative research). DeWorm3 will
use stakeholder mapping and network analysis, qualitative data collection via individual
interviews and focus groups, structural readiness surveys, process mapping, and economic
evaluation methods to assess opportunities to maximize intervention effectiveness, evalu-
ate the efficiency of the intervention relative to the standard-of-care, and identify strate-
gies for sustaining, scaling, and replicating effective components of trial interventions.
The implementation science research described in this protocol will be helpful to policy
makers and program implementers who aim to use DeWorm3 findings to inform guide-
lines and routine programmatic activities. The DeWorm3 implementation science proto-
col is also relevant to researchers interested in incorporating implementation hypotheses
into their own clinical research studies.
Introduction
On average it takes over a decade for clinical research to translate into effective policy and evi-
dence-based practice [1]. However, there is an increased understanding that systematic assess-
ments of the delivery systems, processes, and policies that contextualize clinical research
findings are necessary for ensuring that data are relevant and meaningfully adapted to different
epidemiological and implementation contexts. In particular, the success of neglected tropical
disease (NTD) programs that utilize mass drug administration (MDA) of preventative chemo-
therapies are highly reliant upon strong distribution channels that facilitate programs achiev-
ing high treatment coverage of targeted populations. Given global control and elimination
targets outlined in the World Health Organization (WHO) NTD Roadmap and 2012 London
Declaration, effective and efficient delivery of MDA programs with high coverage and scale is
critical [2].
There are a number of factors that influence MDA coverage in the delivery of routine pro-
grams, including drug supply chains, population enumeration, human resource availability
and capability, and social sensitization and mobilization. These, in addition to other factors,
can be systematically studied through implementation science (IS), which is the scientific prac-
tice of identifying, testing and scaling up effective interventions with high quality, fidelity and
efficiency. IS is increasingly relevant within NTD programs to ensure that innovations and
tools reach populations in need and are appropriately adapted to the local context while main-
taining core elements of proven interventional strategies [3]. Applying these methods requires
multidisciplinary approaches to studying the process of implementation and the translation of
findings into practice. Using IS tools to assess opportunities, address challenges and optimize
innovative approaches to NTD control and elimination programs is inherently important and,
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in light of the Sustainable Development Goals, promotes strong public health delivery systems
in NTD-endemic countries [4].
Clinical trials that incorporate implementation or operational research questions are
referred to as hybrid studies [5]. The DeWorm3 Project was launched in 2016 as a series of
large hybrid trials in Benin, Malawi, and India. The purpose of these trials is to test the feasibil-
ity of interrupting the transmission of soil transmitted helminths (STH) using expanded che-
motherapeutic approaches while concurrently generating information on the opportunities,
challenges, and best-practices for delivering novel STH transmission interruption programs.
DeWorm3 aims to preemptively bridge the “know-do” gap by using IS methods to speed the
evidence translation process needed to inform STH elimination guidelines, public health prac-
tice, and policies and operational plans. By embedding rigorous IS methods within DeWorm3,
we aim to (1) describe the implementation environment that contextualizes clinical research
findings, and (2) if interventions are found to be efficacious, to generate evidence regarding
effective strategies for promoting and scaling-up the interventions to interrupt transmission.
This research builds and expands upon prior NTD implementation research from Uganda [6,
7] and Kenya [8, 9] including the ongoing work by the Tumikia project, another randomized
trial evaluating the impact of intensified deworming on hookworm transmission [10].
Aims and objectives
DeWorm3 is a series of cluster randomized trials evaluating the feasibility of interrupting
transmission of STH using biannual (twice annually) community-wide MDA targeting eligible
community members of all ages. Additionally, DeWorm3 aims to assess the relative influence
of community-wide MDA on STH prevalence and transmission intensity as compared to stan-
dard-of-care targeted MDA. The rationale, objectives, and design of the DeWorm3 Project
clinical trial are described elsewhere in this supplement [11].
The effectiveness of community-wide MDA for STH is driven in part by epidemiological
factors (baseline disease prevalence and STH species distribution), intervention characteristics
(drug efficacy), systems factors (health system strength), and social factors (community mem-
ber beliefs and preferences) that influence intervention acceptability, penetration, and uptake.
These factors are highlighted in the DeWorm3 theoretical model (Fig 1). The overall objective
of DeWorm3 IS research is to evaluate these factors in order to develop and test a community-
wide STH MDA model that is sustainable and scalable in STH-endemic areas. Specific
research aims include:
1. To systematically identify stakeholders influencing standard of care targeted and commu-
nity-wide MDA and map their potential role and involvement in scale-up of community-
wide MDA for STH.
2. To identify implementation-related barriers and facilitators to community-wide MDA for
STH from the perspective of various stakeholders:
a. At baseline, to identify barriers and facilitators (i.e. lessons learned) from other commu-
nity-wide MDA programs, such as lymphatic filariasis (LF) and school-based STH pro-
grams, in order to optimize delivery of community-wide MDA for STH.
b. At midline and endline, to assess barriers and facilitators influencing delivery of commu-
nity-wide MDA for STH and how these barriers and facilitators vary across clusters
achieving high and low treatment coverage.
3. To quantify the readiness of the health system to deliver community-wide MDA for STH
programs:
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a. At baseline, to identify readiness to deliver community-wide MDA for STH programs
b. At endline, to identify readiness to scale-up community-wide MDA for STH programs
and assess changes in readiness over time.
4. To map the intervention delivery process and identify any discrepancies between planned
and implemented activities in order to optimize the trial intervention.
5. To compare the financial and economic costs and incremental cost-effectiveness of com-
munity-wide and targeted MDA for STH in the short- and long-term:
a. To compare the costs and incremental cost-effectiveness of providing six biannual
rounds of community-wide MDA versus three annual rounds of targeted standard of
care MDA program in each study country.
b. To compare the costs and incremental cost-effectiveness of interrupting STH transmis-
sion using a community-wide MDA platform versus a targeted standard of care MDA
program in each study country.
Methods
IS research will be conducted at DeWorm3 baseline (i.e. formative research), midline (i.e. process
research), and endline (i.e. summative research). The purpose of conducting formative research
is to strengthen DeWorm3 implementation by preemptively identifying implementation barriers
and facilitators, seeking support from influential “gatekeepers,” and building consensus. Stake-
holder analysis, qualitative data collection, and readiness assessments will contribute to formative
research, as described below. Process research will provide important information regarding the
contextual factors such as intervention acceptability, uptake, and penetration that influence
observed DeWorm3 trial outcomes. Qualitative data collection and process mapping activities
will contribute to process research. Lastly, summative research will be used to link implementa-
tion factors to key DeWorm3 outcomes (i.e. reductions in prevalence and achievement of trans-
mission interruption) and evaluate how DeWorm3 interventions can be scaled, sustained, or
Fig 1. DeWorm3 theoretical model depicting system of influence on successful community-wide MDA delivery.
https://doi.org/10.1371/journal.pntd.0005988.g001
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translated into meaningful guideline recommendations. Qualitative data collection, readiness
assessments, process mapping, and cost-effectiveness analyses will contribute to summative
research. By tracking key implementation factors from baseline and continuously throughout the
study, we will be able to identify how the DeWorm3 implementation landscape changes over the
duration of the trial.
Stakeholder analysis
Stakeholder analyses will be conducted in each DeWorm3 trial site at baseline (pre-launch),
following trial launch, and at study endline. The purpose of the stakeholder analysis is to iden-
tify the individuals who influence or are influenced by effective targeted MDA and commu-
nity-wide transmission interruption efforts and understand how the network dynamics may
influence study outcomes and future policy development. A social network analysis strategy
will be used to characterize the relationships between stakeholders in order to (1) describe and
map members of the network, (2) characterize the relationship between the network members,
and (3) analyze the network using standard network measures such as density, centrality, and
homophily [12].
Data collection and analysis. A standardized stakeholder mapping exercise will be imple-
mented in all DeWorm3 sites. In the first part of the exercise, working groups composed of the
DeWorm3 IS team, personnel from Ministries of Health and Education, and local commu-
nity-based organizations (CBOs) will identify and describe an exhaustive network of stake-
holders who influence or are affected by school-based MDA and, separately, community-wide
MDA for STH (adapted from [13]). Working groups will identify stakeholders at each level of
the health system, including: the national level; state/regional (or equivalent) level; district (or
equivalent) level; local/health center level; community level, including community drug dis-
tributors (CDDs), community leaders, and community members; and groups external to the
government, including CBOs, non-governmental organizations (NGOs), or international bod-
ies such as WHO.
The stakeholder mapping tool guides the systematic identification of a stakeholder’s influ-
ence on the outcomes of the intervention, their attitude towards the intervention, and oppor-
tunities to engage the stakeholder throughout the duration of DeWorm3 trial. Additional
stakeholders might be added to the network at two follow-up time points, and their attitudes
towards the intervention will be updated over time to document changing acceptability of the
intervention. During the second part of the exercise, DeWorm3 staff will map the relational
power dynamics and dependences between the stakeholders identified by characterizing the
directionality of influence (i.e. who influences who) between the stakeholders and the influ-
ence category, including: supervision, financial support, technical support, or communication
only.
De-identified stakeholder maps in which stakeholder names and affiliations have been
removed will be analyzed using standard network measures to understand if: there are stake-
holders with extensive influence (i.e. degree centrality), there is high interconnectedness across
stakeholders, there are stakeholders who link the network together (i.e. between centrality),
there is density around specific stakeholders that might hinder sustainability, there is integra-
tion across government ministries and external organizations, or if there is the potential for
dysfunctional relationships that might influence intervention effectiveness [12]. Over the dura-
tion of the DeWorm3 trials, stakeholder maps will also be used to explore the association
between stakeholder attitudes and effective implementation in relevant geographic areas in
order to understand if high intervention acceptance of influential stakeholders has a cascade
effect at other levels, thereby positively influencing treatment coverage.
The DeWorm3 implementation science protocol
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Qualitative research
Qualitative research will be conducted at trial baseline, midline, and endline to identify factors
influencing implementation quality, feasibility, and sustainability by site. Qualitative research
will utilize the Consolidated Framework for Implementation Research (CFIR) as a guide for
data collection and analysis. The CFIR is a validated tool utilized in the United States and
increasingly in low- and middle-income countries [14, 15]. The CFIR is built upon a number
of preexisting implementation theories to provide a comprehensive meta-theoretical frame-
work of 39 “constructs” that influence implementation [16]. Application of the CFIR helps
guide theory development and verify whether and why interventions work through the identi-
fication of core and modifiable intervention characteristics [17].
CFIR constructs are organized according to five major domains influencing implementa-
tion effectiveness including: (1) the intervention, (2) the inner setting, (3) the outer settings,
(4) the individuals involved, and (5) the process of undertaking the intervention. The “inter-
vention” is defined as the core characteristics of the planned intervention. The “inner and
outer settings” comprise the contexts where the implementation activities will occur. The
“individuals involved” are the agents of change, those who have power and influence to seek,
experiment with, or evaluate interventions. Lastly, the implementation process describes an
active progression towards attaining the outcome of the intervention described [18]. We have
selected a subset of 21 constructs to assess according to the following salience criteria: (1) is the
construct a potential barrier or facilitator to community-wide MDA for STH? and (2) Would
the construct exhibit heterogeneity across stakeholder groups or clusters? Question guides are
designed to address the targeted constructs and are tailored to the stakeholder level (i.e.
national, district, etc.). Baseline qualitative research will help refine CFIR construct selection
for use during process and summative research as well.
Data collection and analysis. Focus group discussions (FGDs) and individual interviews
will be conducted with stakeholders from all levels of the health system. FGDs with cluster-
level stakeholders will take place in four randomly selected clusters per site, including commu-
nity members, CDDs, and health center staff or CDD supervisors. FGD participants will be
selected using random purposive sampling [19]. Interviews will take place with individuals at
higher levels of the health system. These individuals will be selected using purposive quota
sampling of mutually exclusive key informant groups (i.e. stakeholder levels) [20].
Trained interviewers who are fluent in local language and customs will conduct one-on-
one interviews and small FGDs in private locations with consenting individuals. The inter-
views will be semi-structured key informant interviews with a mix of respondent and infor-
mant style questions. In each site, we use pragmatic criterion to determine the sample size,
influenced by the number of levels of the site’s health system. If it is deemed that data satura-
tion has been achieved and redundancy criterion are met within a given stakeholder group
after 80% of interviews have been conducted in that group, the sample size may be reduced.
All interviews will be audio recorded and transcribed. Transcriptions will be translated to
English. Two primary coders will independently code the site-specific transcripts using CFIR
sub-constructs as analysis guides and coordinate their coding to create a comprehensive code-
book and thematic analysis. Analyses will be based upon a deductive approach[21]. Special
attention will be paid to distinguish factors related to the content and structure of the interven-
tion, opportunities to enhance fidelity of the intervention, penetration within the health sys-
tem, and opportunities to bring the intervention to scale. Similarities and differences in
identified factors will be assessed within and across sites, leveraging the inherent heterogeneity
present across clusters.
The DeWorm3 implementation science protocol
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0005988 January 18, 2018 6 / 13
At midline and endline, qualitative research at the cluster level will take place in four ran-
domly selected clusters per site: two high coverage clusters (80–100% average treatment cover-
age in year 1) and two low/moderate coverage clusters (<80% average treatment coverage in
year 1). CFIR constructs will provide a framework for understanding why the DeWorm3 inter-
vention may exhibit differential effectiveness across settings, correlates of high coverage, and
opportunities to optimize the intervention moving forward. Following thematic coding, two
independent analysts will assign scores to data at a cluster level to distinguish CFIR constructs
that are missing too much data (M), do not distinguish between coverage levels (0), weakly
(+1/-1), or strongly (+2/-2) distinguish coverage levels. The ratings reflect the positive or nega-
tive influence (valence) and strength of each construct on influencing implementation [18].
These relationships will be evaluated using chi-square tests. Findings will be synthesized to
develop recommendations for best practices and highlight barriers and facilitators of imple-
mentation in high and low coverage sites.
Quality control will be ensured through a process of (1) random one minute spot checks of
each transcribed audio file at a site level, (2) coding review and confirmation of 10% of coded
transcripts from each site at the central DeWorm3 level, and (3) coding review and confirma-
tion of 5% of coded transcripts between sites (i.e. circular quality assurance).
Structural readiness to implement
When a health system is preparing to implement a new intervention or to change standard
practice, effective implementation of the change may be influenced by the degree to which
stakeholders identify the system as “ready” to implement the change or practice. Within
DeWorm3, readiness implies that individuals feel empowered as members of the health system
to contribute to the new interventions, they are confident in the flexibility and responsiveness
of the system to adapt to the change, they are not threatened by the change, and they believe
intervention is appropriate for achieving desired outcomes. With the repurposing of commu-
nity-wide LF MDA platforms for STH transmission interruption and a transition from tar-
geted to community-wide MDA, there will be a considerable need for systems adaptation and
a multi-level and multi-faceted assessment of the government and its partners’ readiness to
implement [22].
It is important to understand the factors that drive health system readiness to implement
novel interventions such as community-wide MDA for STH both in order to contextualize
observed trial outputs and outcomes as well as to provide evidence-based guidance in other
settings regarding health system factors that should be in place prior to implementation [23].
Drawing from organizational readiness for change theory, DeWorm3 has developed a struc-
tural readiness assessment survey tool [24]. At baseline, the tool will be used to identify needs
or conditions that can be targeted for effective change management. At study endline, the
readiness tool will be used in a prognostic manner to evaluate health system readiness to sus-
tain or scale-up the intervention [24].
Data collection and analysis. The readiness survey instrument aims to capture an indi-
vidual’s perception of the structural readiness of the health system as well as the downstream
phenomena of psychological readiness. Readiness indicators fall into six domains, including:
the policy environment, leadership structure, financial resources, material resources, technical
capacity, and community delivery infrastructure. Survey questions within each domain are
intended to assess the health system’s readiness to launch the new community-wide MDA
intervention, deliver community-based public health programs, and function collaboratively.
Knowledge assessment questions are used to score a survey participants knowledge of a spe-
cific domain, and weight their responses to domain questions accordingly.
The DeWorm3 implementation science protocol
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The sampling frame for survey participants is defined by the network of individuals identi-
fied during baseline stakeholder mapping and updated over time. Participants will be selected
using restricted random selection to ensure participation from at least 10% of individuals in
each stakeholder group (i.e. national level government staff, CDDs, external partners, etc.),
attain sufficient representation from each stakeholder group, and variation across stakeholder
groups. Random selection of participants at the local level (health center staff and CDDs) will
be restricted to five randomly selected clusters. Surveys will be either self-administered by liter-
ate participants or administered in-person by trained study personnel in the local language.
Mean readiness scores and standard deviations will be calculated by site and stakeholder
group. We will assess concordance between indicator scores within sites using analysis of vari-
ance (ANOVA) models to understand variation in scores amongst and between stakeholder
groups.
Process mapping
Process mapping is a systems analysis approach to identifying the flow of inputs required to
achieve optimal outputs, such as high MDA treatment coverage. Process mapping generates a
systems-wide view of complex, interdependent components that can contribute to effective
MDA programs with high coverage. Process mapping also helps build a shared understanding
of how work is carried out and promotes common organizational goals, while simultaneously
generating information regarding what aspects of the intervention are adaptable across settings
and which are key determinants of intervention uptake.
DeWorm3 will use two process mapping methods. The first is in-depth process mapping,
which will take place annually in six randomly selected clusters over the duration of the trial.
The second is routine workflow mapping, which will take place in each cluster during each
round of MDA. The in-depth process mapping will help identify all activities that must take
place in school or community-based MDA programs, ideal activity levels for achieving opti-
mized outputs, actual activity achievements, and the discrepancy between ideal and actualized
activities. Routine workflow tracking will provide information regarding key activity perfor-
mance in each cluster, and how different activities may or may not be tied to reaching treat-
ment coverage targets. Both of these strategies will identify contextually-relevant modifiable
bottlenecks that may be addressed to improve the intervention delivery process and to achieve
key intervention outputs.
Data collection and analysis. At baseline, implementation science teams in six different
clusters per site will engage in guided in-depth process mapping activities. Clusters will be
selected based on site-specific indications of capacity. In some sites, this may be historical tar-
geted STH coverage, LF coverage, or immunization coverage. We will use restricted randomi-
zation to select two DeWorm3 intervention clusters with high baseline capacity, two
intervention clusters with low baseline capacity, one control cluster with high baseline capac-
ity, and one control cluster with low baseline capacity. By including clusters with heteroge-
neous baseline capacity indications, we augment our ability to observe how the delivery
environment responds to or evolves in the context of the DeWorm3 intervention. IS teams in
each selected cluster will identify all of the activities and the flow of activities necessary for
delivering school-based or community-wide MDA. Ideal metrics and timelines will be identi-
fied for each activity. For example, for the activity of sensitization of village leaders, the ideal
metric may be that 80% of village headmen with phones are called about an upcoming MDA
campaign and the ideal timeline may be one week in advance of drug delivery.
Activity tracking will be ongoing. Once per year, following MDA in both trial arms, selected
clusters will record how each mapped activity actually occurred, including the metrics
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achieved and the relevant time points. This will facilitate analysis of the number of activities
that did not meet ideal benchmarks, and if these activities act as bottlenecks to implementing
subsequent “downstream” activities. T-tests will be performed to identify if there are changes
in the number of activities that do not meet targets within clusters across study years, if certain
activity targets are consistently associated with high or low coverage, as well as if there are dif-
ferences in the number of bottlenecks identified in clusters achieving high or low coverage.
A routine process mapping worksheet will be conducted in all intervention and control
clusters during each round of MDA. These worksheets detail activities that must take place in
the effective delivery of the intervention. Routine mapping provides opportunities to optimize
the intervention in real-time, to systematically measure study inputs and processes, to promote
the replicability of the trial, and to identify trial components that may be easily modified or
adapted with minimal effects on MDA coverage. Observations from the in-depth process map-
ping activities will also be used to refine the routine workflow trackers in order to build a use-
ful monitoring tool that may be applicable in other settings.
Economic research
The financial and economic costs and incremental cost-effectiveness of community-wide and
targeted MDA for STH will be ascertained at the end of the DeWorm3 trial (following three
years of the intervention and two years of surveillance). Using mathematical models, costs and
cost-effectiveness will also be evaluated over a longer time horizon appropriate for an elimina-
tion scenario.
Data collection and analysis. Inputs required to assess the financial and economic costs
of community-wide and targeted MDA for STH will be collected in all DeWorm3 study sites
using a standardized cost collection tool. Aligned with economic evaluation guidelines [25–
27], the tool follows an ingredients-based micro-costing approach for estimating cost of health
interventions; this methodology entails identification and measurement of all inputs required
for the intervention, followed by their conversion into monetary value terms to produce a cost
estimate. The data will be collected throughout the implementation of the DeWorm3 trial.
Data collection rounds will be triggered by site completion of specific trial activities (ex. com-
pleting a cross-sectional survey). Aligning data collection with trial activities and routine
financial reporting will enhance the quality of the cost data collected by minimizing recall bias
and limiting duplication of tasks within the project.
The costs will be assessed from multiple perspectives, namely: individual (i.e. participant),
societal, and health systems (i.e. government). Full incremental costs will be derived. Resource
use will be valued both in terms of financial and economic costs, including time demanded by
community members and Ministry of Health staff to participate in different aspects of the
intervention. The intervention costs will be assessed by activity (i.e. community sensitization,
population census, MDA, etc.) allowing for greater transparency in reporting and broader gen-
eralizability of estimates generated. Within each activity, the contribution of specific, broadly
categorized, programmatic inputs will be distinguished (i.e. drugs, wages and per-diems, mate-
rials and supplies, equipment and overheads, etc.) This will highlight key cost drivers for MDA
interventions. The cost estimates will be summarized annually for each trial arm with total
intervention costs calculated by summing annual costs over the duration of the DeWorm3
trial.
The relative efficiency of community-wide and standard of care targeted MDA for STH as
implemented in the DeWorm3 trials will be assessed by combining the cost estimates with
measures of epidemiological impact of the interventions. A range of outcomes including the
percent reduction from baseline to endline prevalence and the total number of prevalent
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infection case-years averted will be considered to both fully capture the impact of the interven-
tions and allow for comparisons with other studies.
The ultimate goal of DeWorm3 cost-effectiveness research is to provide policy makers and
implementers with information regarding the efficiency of community-wide MDA for STH
elimination in endemic settings. To this end, the trial will generate key epidemiological and
cost data to populate mathematical models of STH epidemiology and control that can also be
used to assess the impact of elimination strategies [28, 29]. The models will produce estimates
of the incremental impact of community wide MDA for STH for settings outside of the
DeWorm3 trial and longer time horizons or 5, 10, 15, 25, and 50 years to appropriately capture
STH elimination scenarios. Long-term costs will be discounted and sources of uncertainty will
be explored in univariate and probabilistic sensitivity analyses [30, 31].
Ethics statement
Participants in individual interviews and focus groups will provide written informed consent.
Participants who are not literate will sign with a thumbprint in the presence of an impartial
witness. Parents of participating children will provide consent on behalf of their child; children
will provide assent in accordance with national ethical guidelines. All qualitative data will be
confidential and all names or identifying information will be encrypted or removed from tran-
scripts to protect the identity of the participants and their associated institutions.
Written consent is not required for participation in readiness surveys, as approved by ethi-
cal review committees. All readiness surveys will be anonymous to protect the identities of par-
ticipants and their relevant institutions. Only the participant’s affiliated stakeholder group will
be recorded.
The IS research component of the DeWorm3 Project has been reviewed and approved by
the Institut de Recherche Clinique au Be´nin (IRCB) through the National Ethics Committee
for Health Research (002-2017/CNERS-MS) from the Ministry of Health in Benin, The Lon-
don School of Hygiene and Tropical Medicine (12013), The College of Medicine Research Eth-
ics Committee (P.04/17/2161) in Malawi, Christian Medical College in Vellore, and KEM
Hospital Research Centre Ethics Committee (1718 and 1719). The study was also approved by
The Human Subjects Division at the University of Washington (STUDY00000180).
Conclusion
The DeWorm3 Project aims to generate additional evidence necessary to optimize the delivery
of evidence based interventions tested within the DeWorm3 trials. Regardless of the trial out-
comes, these data will contribute to the ability of policy makers and STH programs to deliver
high-quality targeted or community-wide MDA at scale. We will utilize recognized dissemina-
tion frameworks to ensure that optimal dissemination routes are established early in trial
implementation [32]. Results will be disseminated to community members and health workers
in trial sites, Ministries of Health in endemic countries, funders, implementing partners, and
policymakers at the World Health Organization.
Embedding implementation science methods within the DeWorm3 trial provides an oppor-
tunity to study the mechanisms that contribute to acceptable, efficient, and effective commu-
nity-wide and population targeted MDA. Stakeholder analysis, framework-based qualitative
research, structural readiness assessments, process mapping, and cost-effectiveness research will
generate the multidisciplinary evidence needed to identify best practices in implementation,
core and adaptable components of the intervention across settings, and considerations for sus-
taining and scaling-up community-wide MDA for STH transmission interruption. Implement-
ing a hybrid trial at such a large scale also provides an opportunity to evaluate opportunities to
The DeWorm3 implementation science protocol
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embed IS into clinical trial work across heterogeneous settings, which may be relevant for other
areas of disease focus.
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